medigraphic.com

2017, Number 4

<< Back

Rev Clin Esc Med 2017; 7 (4)

Efectividad de Trastuzumab en combinación con terapia sistémica en pacientes con cáncer de mama avanzados o metastásico HER2 positivos. Experiencia del Hospital México, Costa Rica

Molina JP, Landaverde DU

Language: Spanish
References: 33
Page: 28-39
PDF size: 415.92 Kb.


ABSTRACT

Introduction: We report the effectiveness and safety profile of trastuzumab in combination with systemic treatments in an unselected group of patients with unresectable locally advanced and/or metastatic HER2 positive breast cancer. This is a single center experience of the initial five years’ experience of trastuzumab in Hospital Mexico- Costa Rica.
Materials and Methods: This is a retrospective and observational study of patients with HER2 positive locally advanced or metastatic breast cancer, between Jan 2006 and Dec 2011. HER2 status was confirmed by imnunohistochemistry (3+) or fluorescence in situ hybridization (FISH). We report here the data from the addition of trastuzumab to any systemic treatment used, including anti-hormonal drugs. We included patients with brain metastases, as well as patients who received trastuzumab in the adjuvancy.
Results: A total of 301 records were found but only 39 of them fulfill all the inclusion criteria. 28 patients (65%) received trastuzumab as first line regimen. 29 patients (67%) received trastuzumab plus paclitaxel. The median time to progression with first line chemotherapy regimen with trastuzumab was 6.56 months (CI 95% 3.57-9.65 months). The median survival reported with chemotherapy plus trastuzumab was 33.5 months (CI 95% 22.1- 44.8 months). Three symptomatic cardiac events were reported, and this cause a temporary withdrawal of the trastuzumab administration. There was a tendency of superior in median overall survival in patients with positive estrogen receptor status but it was not statistically significant (log rank 0.066).
Conclusion: In this group of unselected patients attended in our Institution, the use chemotherapy plus trastuzumab was associated with a median time to progression and overall survival very similar to the experience reported in the pivotal trials of trastuzumab. And also de cardio-toxicity was mild in this Latin American population


REFERENCES

  1. Niño LAG, Garavito AÁ, Jaramillo CE, Velásquez SJ, Corcho RDS, Bernal BHA. Cáncer de mama: HER2/neu, métodos diagnósticos y consideraciones clínicas. Rev Colomb Cancerol. 2007;11(1):40-57.

  2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.

  3. Holleczek B, Jansen L, Brenner H. Breast cancer survival in Germany: a population-based high resolution study from saarland. PloS one. 2013;8(7):e70680.

  4. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov;16(11):1772-7.

  5. McCormack VA, Joffe M, van den Berg E, Broeze N, dos Santos Silva I, Romieu I, et al. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. Breast Cancer Res. 2013;15(5):R84.

  6. Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V. The association of HER-2/neu amplification with breast cancer recurrence. Archives of Surgery. 2000;135(12):1469-74.

  7. Papazisis K, Habeshaw T, Miles D. Safety and efficacy of the combination of trastuzumab with docetaxel for HER2‐positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. Int J Clin Pract. 2004;58(6):581-6.

  8. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-smallcell lung cancer: current knowledge and future directions. J Clin Oncol. 2005 Apr 10;23(11):2556-68.

  9. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8(4):307-25.

  10. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004;9(4):361-77.

  11. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg Å, Grénman S, et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. The American journal of pathology. 2000;156(3):839-47.

  12. Landaverde D, Verma S. Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach. Clinical Practice. 2012;9(3):287-99.

  13. Extra JM, Antoine EC, Vincent- Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist. 2010;15(8):799-809.

  14. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 1;20(3):719-26.

  15. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74.

  16. Milani A, Montemurro F, Gioeni L, Aglietta M, Valabrega G. Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer (Dove Med Press). 2010 Nov 24;2:93-109.

  17. Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, et al. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathology & Oncology Research. 2011;17(3):753-8.

  18. Singh R, Gupta S, Pawar SB, Pawar RS, Gandham SV, Prabhudesai S. Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India. J Cancer Res Ther. 2014 Jan-Mar;10(1):26-8.

  19. Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2- positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol. 2013 Feb;24(2):283- 91.

  20. Puig-Vives M, Sanchez M, Sanchez- Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish populationbased study. Gynecol Oncol. 2013;130(3):609-14.

  21. Telli M, Kurian A, Chang E, Keegan T, Ford J, Gomez S. Asian race and breast cancer subtypes: a study from the California Cancer Registry. ASCO Annual Meeting Proceedings; ; 2008.

  22. Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer. 2011;11(1):1.

  23. Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, et al. Triple positive breast cancer: a distinct subtype? Cancer Treat Rev. 2015;41(2):69-76.

  24. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010 Jul 10;28(20):3271-7.

  25. Song Q, Huang R, Li J, Fan J, Zheng S, Zhang B, et al. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10- year retrospective multi-center study in China. PloS one. 2013;8(8):e72175.

  26. Gaedcke J, Traub F, Milde S, Wilkens L, Stan A, Ostertag H, et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Modern pathology. 2007;20(8):864-70.

  27. Clayton AJ, Danson S, Jolly S, Ryder WDJ, Burt PA, Stewart AL, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91(4):639-43.

  28. Láng I, Bell R, Feng F, Lopez R, Jassem J, Semiglazov V, et al. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the Retreatment after HErceptin Adjuvant trial. Clin Oncol. 2014;26(2):81-9.

  29. Vicente C, Serrano N, Agustín MJ, Alonso V, Palomo P, Huarte R. Cardiotoxicidad asociada a trastuzumab en la práctica clínica asistencial. Farmacia Hospitalaria. 2009;33(4):202-7.

  30. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006 Sep 1;24(25):4107-15.

  31. Perez EA. Cardiac toxicity of ErbB2- targeted therapies: what do we know? Clinical breast cancer. 2008;8:S114-20.

  32. Fedele C, Riccio G, Malara AE, D’Alessio G, De Lorenzo C. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat. 2012;134(2):595-602.

  33. Tsai H, Isaacs C, Fu A, Warren J, Freedman A, Barac A, et al. Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population- based study. Breast Cancer Res Treat. 2014;144(1):163-70.




2020     |     www.medigraphic.com